EGF Theramed Health Corp. (CNSX: TMED.X)
Health Care · Pharmaceuticals · CA
CA$0.06
— today · -31.3% 1Y
EGF Theramed Health Corp. (CNSX: TMED.X) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $458.67K.
Over the last twelve months the share price has lost 31.3%, trading between 0.06 and 0.13.
Tweenvest scores EGF Theramed Health Corp. across four factors: quality 6/100. Its strongest factor is quality.
TMED.X price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $458.67K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.26
- Dividend yield
- —
- Beta (5Y)
- 0.27
- 52-week high
- CA$0.13
- 52-week low
- CA$0.06
- Avg volume (3M)
- —
- Shares outstanding
- 11.62M
- Employees
- —
- Next earnings
- —
About EGF Theramed Health Corp.
EGF Theramed Health Corp. focuses on providing psychedelic-based therapies to address various mental health challenges. The company's products are specifically utilized in the treatment of conditions such as intractable depression, anxiety disorders, post-traumatic stress disorder (PTSD), and general depression. Established in 2011, this firm operates from its main headquarters in Vancouver, Canada.
- Listed since
- Jul 5, 2013
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.35 | +0.16% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.15 | +0.29% |
Figures last refreshed Aug 18, 2026.